Vanberra Signal

Alto Neuroscience

Curated by Signal

AI-driven drug discovery platform for neurological diseases based on patients biomarkers

Overview

AI-driven drug discovery platform for neurological diseases based on patients biomarkers. The company's platform measures patients biomarkers like EEG and wearable data, behavioral patterns, genetics, and other factors to develop personalized psychiatric drugs. The company has pipeline of drugs including ALTO-100 for depression, ALTO-101 for neurodegenerative diseases, and more.

Key facts

Founded
2019

Business model

Contact

Open roles

25 roles
  • Associate Director, Clinical Operations: People & Functional Leadership

    Mountain View, CA · On-site · Volunteer

  • Manager, Patient Recruitment & Engagement

    Mountain View, CA · On-site · Volunteer

  • Senior Manager/Director of Procurement

    Mountain View, CA · On-site · Volunteer

+ 22 more open roles on Signal

More on Vanberra Signal

Members only

Competitors & similar companies

More Life Sciences Technology companies
  • Brand of healthcare & nutrition products

    Life Sciences TechnologyJersey City, United States
  • Developer of prosthetics for limb amputees

    Life Sciences TechnologyUnited States
  • Developer of multi omic solutions for the diagnosis and management of diseases

    Life Sciences TechnologyPhoenix, United States

About Alto Neuroscience

What does Alto Neuroscience do?

AI-driven drug discovery platform for neurological diseases based on patients biomarkers.

Where is Alto Neuroscience headquartered?

Alto Neuroscience is headquartered in San Francisco, United States.

When was Alto Neuroscience founded?

Alto Neuroscience was founded in 2019.

Which sector is Alto Neuroscience in?

Alto Neuroscience operates in Life Sciences Technology.

Who are Alto Neuroscience's competitors?

Companies similar to Alto Neuroscience include Freshly Moms, NeuroX Innovations, and Cirrus Bio.

Is Alto Neuroscience hiring?

Yes. Alto Neuroscience has 25 open roles listed on Vanberra Signal.